Literature DB >> 28507024

Cutting Edge: Differential Fine-Tuning of IL-2- and IL-15-Dependent Functions by Targeting Their Common IL-2/15Rβ/γc Receptor.

Dihia Meghnem1, Sébastien Morisseau1,2, Marie Frutoso1, Kilian Trillet1, Mike Maillasson1, Isabelle Barbieux1, Sarah Khaddage1, Isabelle Leray1, Markus Hildinger3, Agnès Quéméner1, Yannick Jacques1, Erwan Mortier4.   

Abstract

Interleukin 2 and IL-15 are two closely related cytokines, displaying important functions in the immune system. They share the heterodimeric CD122/CD132 receptor to deliver their signals within target cells. Their specificity of action is conferred by their α receptor chains, IL-2Rα and IL-15Rα. By combining an increased affinity for CD122 and an impaired recruitment of CD132, we have generated an original molecule named IL-2Rβ/γ (CD122/CD132) inhibitor (BiG), targeting the CD122/CD132 receptor. BiG efficiently inhibited IL-15- and IL-2-dependent functions of primary cells, including CD8 T and NK cells, in vitro and in vivo. We also report a differential dynamic of action of these cytokines by highlighting a major role played by the IL-2Rα receptor. Interestingly, due to the presence of IL-2Rα, BiG had no impact on IL-2-dependent regulatory T cell proliferation. Thus, by acting as a fine switch in the immune system, BiG emphasizes the differential roles of these two cytokines.
Copyright © 2017 by The American Association of Immunologists, Inc.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28507024     DOI: 10.4049/jimmunol.1700046

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  8 in total

1.  CD122 blockade restores immunological tolerance in autoimmune type 1 diabetes via multiple mechanisms.

Authors:  Xiaomei Yuan; Yi Dong; Naoya Tsurushita; J Yun Tso; Wenxian Fu
Journal:  JCI Insight       Date:  2018-01-25

2.  Selective Targeting of IL-15Rα Is Sufficient to Reduce Inflammation.

Authors:  Dihia Meghnem; Mike Maillasson; Isabelle Barbieux; Sébastien Morisseau; Dalloba Keita; Yannick Jacques; Agnès Quéméner; Erwan Mortier
Journal:  Front Immunol       Date:  2022-05-03       Impact factor: 8.786

3.  Tumor cell-expressed IL-15Rα drives antagonistic effects on the progression and immune control of gastric cancer and is epigenetically regulated in EBV-positive gastric cancer.

Authors:  Jing Wei; Chen Guo; Xiang An; Wenxuan Miao; Chenli Zhang; Binsheng Wang; Wei Cai; Min Li; Fangfang Zhang
Journal:  Cell Oncol (Dordr)       Date:  2020-08-07       Impact factor: 6.730

4.  Antibody blockade of IL-15 signaling has the potential to durably reverse vitiligo.

Authors:  Jillian M Richmond; James P Strassner; Lucio Zapata; Madhuri Garg; Rebecca L Riding; Maggi A Refat; Xueli Fan; Vincent Azzolino; Andrea Tovar-Garza; Naoya Tsurushita; Amit G Pandya; J Yun Tso; John E Harris
Journal:  Sci Transl Med       Date:  2018-07-18       Impact factor: 17.956

Review 5.  Role of interleukin-15 in cardiovascular diseases.

Authors:  Lei Guo; Ming-Fei Liu; Ji-Niu Huang; Jia-Min Li; Jun Jiang; Jian-An Wang
Journal:  J Cell Mol Med       Date:  2020-05-14       Impact factor: 5.310

6.  Simulation of Stimulation: Cytokine Dosage and Cell Cycle Crosstalk Driving Timing-Dependent T Cell Differentiation.

Authors:  Matteo Barberis; Tomáš Helikar; Paul Verbruggen
Journal:  Front Physiol       Date:  2018-08-02       Impact factor: 4.566

7.  TPD7 inhibits the growth of cutaneous T cell lymphoma H9 cell through regulating IL-2R signalling pathway.

Authors:  Man Zhu; Liu Yang; Xianpeng Shi; Zhengyan Gong; Runze Yu; Dongdong Zhang; Yanmin Zhang; Weina Ma
Journal:  J Cell Mol Med       Date:  2019-11-19       Impact factor: 5.310

8.  Interleukin-15 response signature predicts RhCMV/SIV vaccine efficacy.

Authors:  Fredrik Barrenäs; Scott G Hansen; Lynn Law; Connor Driscoll; Richard R Green; Elise Smith; Jean Chang; Inah Golez; Taryn Urion; Xinxia Peng; Leanne Whitmore; Daniel Newhouse; Colette M Hughes; David Morrow; Kurt T Randall; Andrea N Selseth; Julia C Ford; Roxanne M Gilbride; Bryan E Randall; Emily Ainslie; Kelli Oswald; Rebecca Shoemaker; Randy Fast; William J Bosche; Michael K Axthelm; Yoshinori Fukazawa; George N Pavlakis; Barbara K Felber; Slim Fourati; Rafick-Pierre Sekaly; Jeffrey D Lifson; Jan Komorowski; Ewelina Kosmider; Danica Shao; Wenjun Song; Paul T Edlefsen; Louis J Picker; Michael Gale
Journal:  PLoS Pathog       Date:  2021-07-06       Impact factor: 6.823

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.